Wellington, NZ, 20th September 2016: Volpara Health Technologies (“Volpara”; ASX:VHT), a digital health company focused on early detection of breast cancer, is pleased to advise that it delivered a public presentation at the National Mammography Quality Assurance Advisory Committee (NMQAAC) meeting hosted by the United States Food and Drug Administration (FDA) on 15 September 2016.
Dr Ralph Highnam, CEO of Volpara said: “This meeting was very important as it gave us insights into how the FDA is moving with regards to quality control in mammogram screening and the need to report breast density to patients. It allowed us to present to the FDA and the wider Committee our new developments in these areas, namely Volpara Enterprise with its automated quality control functions.”
For further information please download PDF attached:
Download this document
